2022
Long-term safety of ketamine and esketamine in treatment of depression
Nikayin S, Murphy E, Krystal JH, Wilkinson ST. Long-term safety of ketamine and esketamine in treatment of depression. Expert Opinion On Drug Safety 2022, 21: 777-787. PMID: 35416105, DOI: 10.1080/14740338.2022.2066651.Peer-Reviewed Original ResearchConceptsLong-term safetyClinical trialsRacemic ketamineLong-term safety effectsRapid-acting antidepressant effectsLower urinary tract symptomsKetamine/esketamineTreatment-resistant depressionUrinary tract symptomsCommon side effectsTreatment of depressionLong-term impairmentElevated heart ratePhase three clinical trialsTract symptomsAntidepressant effectsBlood pressureIncreased riskBladder pathologyEsketamineHeart ratePsychiatric disordersSide effectsCognitive impairmentHigh doses
2013
Psychiatric aspects of primary immunodeficiency diseases: the parental study.
Abolhassani H, Aghamohammadi A, Pourjabbar S, Salehi Sadaghiani M, Nikayin S, Rabiee A, Imanzadeh A, Mahmmoodi Gharaei J, Arbabi M, Rezaei N. Psychiatric aspects of primary immunodeficiency diseases: the parental study. Iranian Journal Of Allergy Asthma And Immunology 2013, 12: 176-81. PMID: 23754357.Peer-Reviewed Original ResearchConceptsPID patientsPsychiatric aspectsComplications of treatmentPrimary immunodeficiency diseasesLong-term illnessPID groupPatient complaintsPsychiatric effectsImmunodeficiency diseaseSide effectsDisease consistPatientsIncurable diseaseReliable questionnaireSuccessful managementTotal scoreParental studiesDiseaseLonger durationSignificant differencesChildrenPsychological counselingComplaintsAnxietyGroup